Skip to Content

Join the 'Akovaz' group to help and get support from people like you.

Akovaz News

Flamel Technologies Receives FDA Approval of Akovaz (ephedrine sulfate) for Surgical Hypotension

Posted 3 May 2016 by Drugs.com

LYON, FRANCE--(Marketwired - May 2, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's New Drug Application (NDA) for Akovaz™ (ephedrine sulfate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulfate. Flamel expects to launch Akovaz during the third quarter 2016 in a strength of 50 mg/mL. "We are very excited to receive FDA approval for Akovaz, the third product from our Éclat portfolio, and in line with the PDUFA date expectations. Revenue expectations associated with this product were included in our previously issued 2016 revenue guidance of $110 - $130 million. Our Éclat portfolio of products, which in ... Read more

Related support groups: Surgery, Anesthesia, Hypotension, Ephedrine, Akovaz

Ask a Question

Further Information

Related Condition Support Groups

Hypotension

Akovaz Patient Information at Drugs.com